Monoclonal antibody-based therapies for microbial diseases - Wikidata - thesis-toulmin - TriplyDB

Monoclonal antibody-based therapies for microbial diseases

Monoclonal antibody-based therapies for microbial diseases

http://www.wikidata.org/entity/Q27490830

about

Nonspecific effect of Mycograb on amphotericin B MIC Immunogenetic mechanisms driving norovirus GII.4 antigenic variation An update on antibody-based immunotherapies for Clostridium difficile infection Antibody-Based Strategies to Prevent and Treat Influenza Monoclonal Antibody Combinations that Present Synergistic Neutralizing Activity: A Platform for Next-Generation Anti-Toxin Drugs Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies.A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models.Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening.Flow cytometry-assisted Monte Carlo simulation predicts clonogenic survival of cell populations with lognormal distributions of radiopharmaceuticals and anticancer drugs.Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases A technology for developing synbodies with antibacterial activity A high-affinity native human antibody neutralizes human cytomegalovirus infection of diverse cell types Role of B cells and antibodies in acquired immunity against Mycobacterium tuberculosis.Principles and application of antibody libraries for infectious diseases.Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of RG7667, an Anticytomegalovirus Combination Monoclonal Antibody Therapy, in Healthy Adults.Monoclonal Antibody Targeting Staphylococcus aureus Surface Protein A (SasA) Protect Against Staphylococcus aureus Sepsis and Peritonitis in Mice.Monoclonal antibodies and toxins--a perspective on function and isotype.A method to predict response of cell populations to cocktails of chemotherapeutics and radiopharmaceuticals: validation with daunomycin, doxorubicin, and the alpha particle emitter (210)Po.Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease.B cells and antibodies in the defense against Mycobacterium tuberculosis infection Enhanced virulence of Histoplasma capsulatum through transfer and surface incorporation of glycans from Cryptococcus neoformans during co-infection.Disease-enhancing antibodies improve the efficacy of bacterial toxin-neutralizing antibodies Combinations of monoclonal antibodies to anthrax toxin manifest new properties in neutralization assays.A simple methodology for conversion of mouse monoclonal antibody to human-mouse chimeric form.Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers LptD is a promising vaccine antigen and potential immunotherapeutic target for protection against Vibrio species infection.Antibody-Based Immunotherapy To Treat and Prevent Infection with Hypervirulent Klebsiella pneumoniae.Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients.Dual targeting strategies with bispecific antibodies.Predicting the Uncertain Future of Aptamer-Based Diagnostics and Therapeutics.Current Status and Development of Vaccines and Other Biologics for Human Rabies Prevention.Metal-Based Nanoparticles for the Treatment of Infectious Diseases.A Human Biofilm-Disrupting Monoclonal Antibody Potentiates Antibiotic Efficacy in Rodent Models of both Staphylococcus aureus and Acinetobacter baumannii Infections.A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza B Virus Monoclonal Antibody, MHAB5553A, in Healthy Volunteers.Characterization of the antifungal functions of a WGA-Fc (IgG2a) fusion protein binding to cell wall chitin oligomers Rationale and design of ASPIRE-ICU: a prospective cohort study on the incidence and predictors of Staphylococcus aureus and Pseudomonas aeruginosa pneumonia in the ICU.Containing the contagion: treating the virus that inspired the film.Pharmacokinetics and exposure-response analysis of RG7667, a combination of two anti-cytomegalovirus monoclonal antibodies, in a Phase 2a randomized trial to prevent cytomegalovirus infection in high-risk kidney transplant recipients.The Role of Natural Antibodies to CC Chemokine Receptor 5 in HIV Infection.Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy.

P2860

Q24632922-9283959E-575A-4696-B555-6CFFBC483BAE Q24810360-ED596B54-E852-4630-B5C9-FCB69AD1AB86 Q26740788-56D63529-EABF-449B-A787-21FCC4F40BE2 Q26798520-3E48520D-8345-4864-830D-094DC352374A Q26863621-36D0AFC2-3B89-4344-8908-53B685D0EB07 Q30374373-A4925FB2-6E60-49E4-A265-25D230958827 Q30408273-0B0924A5-9D52-40F5-9B00-226FF69497CD Q30423024-3FAB76C7-A1C0-49AF-889B-936D57AAB55C Q33642550-EB82E04E-17AC-4601-B43A-31916883AACA Q34536782-AA581FD1-D5B1-4F87-A9F5-FDB0791B3DAC Q34570999-04EAD425-6747-44CA-8235-1B8B6798EC4B Q35076970-D4CD2EC4-3E01-4AF7-8A48-C81CEF034116 Q35164284-21C97E16-5E22-42CD-8E2F-05D3902A6A8D Q35249355-9CBFBAB1-239B-4D2A-B1E3-7FEF51DD4785 Q35859879-49296D28-1E7D-44C9-A186-7F925449917A Q35939497-28F73AFF-3FA6-4E32-96B1-44F3D6501312 Q36099489-CC944395-5779-4AC2-B168-E7D8772C9C17 Q36103417-D63B7F08-68F6-48CC-AD28-69BF40E03244 Q36108119-1DA08C75-53BA-443C-A503-8061D044F1BE Q36238031-9FD29E64-A0E0-4710-AAD7-DD19B63DD4A7 Q36610943-3AD9C74B-17D0-4C74-A09F-A3AD6878F633 Q36786293-27A34A27-202C-4B62-8981-93C97CD1AF71 Q36911369-00344A5C-DA9A-4C74-87DA-A0FAF2D17EDF Q37178059-3176DF1F-734B-4958-A403-E18D2458C571 Q37203832-CB164797-F0C1-4CCA-8CCD-1CC8B306B12D Q37475910-E5F4A04A-D080-4B34-B294-3DC4FAD3AF71 Q37563608-6EF9E2A6-B05C-4FF9-B13B-525956031A9D Q37612990-1576373C-D0BE-41D6-A53D-7567612E5272 Q37997559-E44DD10C-F4E1-4616-ABE1-73FC4C34C8B6 Q38443249-6168066D-5D96-4496-83A4-006CCEB27066 Q39414342-487F7C85-FB52-4D04-BC9F-7E486E12683E Q40078347-92F5E85C-A3EA-4881-868C-650240600FE0 Q40131084-E8D85AC7-FE28-48FB-BBBB-EF11A5339BE4 Q40180049-272D8A9B-1426-4E3D-B5E5-DFB3C8A58BC0 Q41842506-4D705744-1A52-494C-92D7-FCCECC1C0698 Q41994425-2224D105-3D68-45EC-A1FE-417BA6760C4B Q42083225-27632972-52EE-4853-B454-50DAB7CBAC9C Q45967035-015C71DE-DA3A-4E15-A438-70D0CD94567E Q47107303-1C6DF7AB-6C53-41FB-949C-AF42C4BE4D97 Q47174470-F3E665FF-7F35-47DA-B4D1-CAF0A42B316A

P2860

Monoclonal antibody-based therapies for microbial diseases

http://www.wikidata.org/entity/Q27490830

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Monoclonal antibody-based therapies for microbial diseases

@ast

Monoclonal antibody-based therapies for microbial diseases

@en

Monoclonal antibody-based therapies for microbial diseases

@nl

type

label

Monoclonal antibody-based therapies for microbial diseases

@ast

Monoclonal antibody-based therapies for microbial diseases

@en

Monoclonal antibody-based therapies for microbial diseases

@nl

prefLabel

Monoclonal antibody-based therapies for microbial diseases

@ast

Monoclonal antibody-based therapies for microbial diseases

@en

Monoclonal antibody-based therapies for microbial diseases

@nl

P1433

Q27490830-C4CBFDDC-39A3-497B-80AA-0BD2C980F70F

P1476

Q27490830-2CB58218-4516-4F51-A0F2-776992E9FD3A

P2093

Q27490830-1154F912-1155-4C45-A527-45171419B5B5

Q27490830-A15B1210-5AA4-499D-A6E9-7270A3B8C541

P2860

Q27490830-01F8397B-276A-40AD-B5D7-EBD854191329

Q27490830-0787D244-95E1-4AA7-BD6A-1AD847AD6CAE

Q27490830-0876DF40-D764-4C42-8F32-7CECFD5C0170

Q27490830-098D534D-7FCE-4603-93F6-D800E48D558C

Q27490830-0C9C7820-6D69-4320-BA37-02DD7CD815F2

Q27490830-0E37593B-55A3-47AC-918B-598C1F6C3D09

Q27490830-0E47FB05-94A5-4B10-ADBB-A9977EC63DA9

Q27490830-10E67CE6-632C-4DE0-81D0-36D0FB5E3C8D

Q27490830-174CBF26-9E30-46A9-AEC5-A88A7D98EDAE

Q27490830-1BFC756A-8A86-4484-953C-317820D951B0

P304

Q27490830-89ADEBBD-2257-4180-9945-6E2989FAEFA6

P31

Q27490830-518F2C10-EE30-42B6-8C53-B2FDBCE3CF6A

P3181

Q27490830-9F5E67DD-9419-44ED-94DF-035B0F598EE0

P356

Q27490830-6E180FBC-6FD6-4DD9-8DF8-9C4392359AC7

P407

Q27490830-13D515EA-9ACA-4436-8F6A-CDA4FBB833AE

P478

Q27490830-9730DEFC-B043-44BE-8EEE-C71930BAA73B

P50

Q27490830-323C0BCE-90FA-4753-8E4E-FC19E29E2BF4

P577

Q27490830-BEEBCCE1-2F99-440A-A1A6-97FDFDF2D719

P5875

Q27490830-841282CC-9709-4508-B21B-ADA6936B601A

P698

Q27490830-1E3163D3-597F-4CCB-AB7A-8F260B316D12

P921

Q27490830-57558FCC-7642-4309-8690-069D114F3009

P932

Q27490830-80C24EA0-9774-4D78-8C45-E0716789B1F9

P3181

P356

J.VACCINE.2009.09.105

P1433

P1476

Monoclonal antibody-based therapies for microbial diseases

@en

P2093

Carolyn Saylor

http://www.w3.org/2001/XMLSchema#string

Ekaterina Dadachova

http://www.w3.org/2001/XMLSchema#string

P2860

Influenza virus antigenic variation, host antibody production and new approach to control epidemics

Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells

CCR5 monoclonal antibodies for HIV-1 therapy

Passive immunity in prevention and treatment of infectious diseases

Anti-alpha-hemolysin monoclonal antibodies mediate protection against Staphylococcus aureus pneumonia

Antibody recognition of a highly conserved influenza virus epitope

Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection

Mutations in Hepatitis C Virus E2 Located outside the CD81 Binding Sites Lead to Escape from Broadly Neutralizing Antibodies but Compromise Virus Infectivity

Progress on the development of therapeutics against West Nile virus

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

P304

G38-46

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4371559

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.VACCINE.2009.09.105

http://www.w3.org/2001/XMLSchema#string

P407

P478

27 Suppl 6

http://www.w3.org/2001/XMLSchema#string

P50

Arturo Casadevall

P577

2009-12-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51440663

http://www.w3.org/2001/XMLSchema#string

P698

20006139

http://www.w3.org/2001/XMLSchema#string

P921

P932

2810317

http://www.w3.org/2001/XMLSchema#string